Axis Bioservices Limited

𝐀𝐱𝐢𝐬 𝐁𝐢𝐨𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬’ 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 𝐨𝐧 𝐐𝐈𝐌𝐀 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬’ 𝟐𝟎𝟐𝟓 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 𝐀𝐫𝐭𝐢𝐜𝐥𝐞!   The recent oncology review shared by our parent company, QIMA Life Sciences, highlights several important key shifts in the industry; including the rise of 𝐀𝐈‑𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲, the growing integration of 𝐚𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐦𝐨𝐝𝐞𝐥𝐬 within a hybrid testing landscape, and 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐝 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐦𝐨𝐝𝐚𝐥𝐢𝐭𝐢𝐞𝐬 such as ADCs.   These developments reflect a broader move towards more 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜, 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦‑𝐝𝐫𝐢𝐯𝐞𝐧 𝐮𝐬𝐞 𝐨𝐟 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐝𝐞𝐥𝐬. As our Managing Director, Dr Jenny Worthington noted in her recent expert commentary, we anticipate the field progressing towards more focused mechanistic in‑vivo studies with reduced reliance on large, resource‑intensive xenograft programmes; all whilst maintaining the scientific value these models provide when used appropriately.   At Axis Bioservices Limited, we are investing in innovation and refining our oncology models and study designs to support this shift; ensuring our approach aligns with a landscape that increasingly prioritises translational relevance, data quality, and thoughtful model selection.   📖 Tap the link below to read the full QIMA LS article and explore how these trends are shaping preclinical decision‑making: https://lnkd.in/gtDSnB3T   #CancerResearch #DrugDevelopment #OncologyInnovation #AxisBioservices #QIMALifeScience #QIMAOncology

𝗔𝘅𝗶𝘀 𝗕𝗶𝗼𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀: 𝗙𝗔𝗖𝗦 𝗼𝗿 𝗙𝗶𝗰𝘁𝗶𝗼𝗻 𝗙𝗿𝗶𝗱𝗮𝘆! We're back with another myth buster: ✅ 𝗙𝗔𝗖𝗦: Ignoring the tumour micro-environment limits the predictive power of preclinical studies. ❌ 𝗙𝗶𝗰𝘁𝗶𝗼𝗻: Anti‑cancer efficacy is fully explained by tumour‑intrinsic responses. In reality, 𝐭𝐡𝐞 𝐓𝐌𝐄 (𝐢𝐦𝐦𝐮𝐧𝐞 𝐜𝐞𝐥𝐥𝐬, 𝐬𝐭𝐫𝐨𝐦𝐚𝐥 𝐜𝐨𝐦𝐩𝐨𝐧𝐞𝐧𝐭𝐬, 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐭𝐮𝐫𝐞, 𝐜𝐲𝐭𝐨𝐤𝐢𝐧𝐞𝐬 𝐚𝐧𝐝 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐩𝐫𝐞𝐬𝐬𝐮𝐫𝐞𝐬) 𝐩𝐥𝐚𝐲𝐬 𝐚 𝐝𝐞𝐜𝐢𝐬𝐢𝐯𝐞 𝐫𝐨𝐥𝐞 in whether or not a therapy succeeds or fails with treatments targeting immunomodulation, angiogenesis or stromal architecture requiring models which reflect these complexities. Without incorporating the TME, context programmes risk 𝐨𝐯𝐞𝐫𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐢𝐧𝐠 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲, missing resistance mechanisms, or selecting the wrong biomarkers for clinical use. - At Axis Bioservices Limited, our expertise in 𝐬𝐲𝐧𝐠𝐞𝐧𝐞𝐢𝐜 𝐦𝐨𝐝𝐞𝐥𝐬, 𝐢𝐦𝐦𝐮𝐧𝐨𝐩𝐡𝐞𝐧𝐨𝐭𝐲𝐩𝐢𝐧𝐠, 𝐟𝐥𝐨𝐰 𝐜𝐲𝐭𝐨𝐦𝐞𝐭𝐫𝐲 𝐚𝐧𝐝 𝐭𝐮𝐦𝐨𝐮𝐫‑𝐢𝐦𝐦𝐮𝐧𝐞 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 enables studies that generate a more complete, clinically relevant picture of therapeutic impact. 𝗦𝗼 𝘄𝗵𝗮𝘁’𝘀 𝗿𝗲𝗮𝗹𝗹𝘆 𝗵𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴 𝗶𝗻 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲? Does overlooking the role of the TME result in overly optimistic efficacy predictions, insufficient characterisation of immune involvement and resistance? - or does limited immune readout integration complicate clinical translation? 𝗦𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗱𝗲𝗿 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀! - How do you incorporate TME understanding into your preclinical strategy? - Where do you see the biggest gaps between model biology and clinical reality? Let’s challenge the boundaries of oncology together! #FACSOrFictionFriday #AxisBioservices #TME #CancerImmunology #OncologyResearch #SyngeneicModels #ImmunoOncology

𝐀𝐱𝐢𝐬 𝐁𝐢𝐨𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐈𝐬 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 - 𝐅𝐢𝐧𝐚𝐥 𝐂𝐚𝐥𝐥; 𝐉𝐨𝐢𝐧 𝐎𝐮𝐫 𝐓𝐞𝐚𝐦 🚀!   As we continue to expand our capabilities in preclinical research, we are seeking a talented 𝐒𝐞𝐧𝐢𝐨𝐫 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐬𝐭 𝐈/𝐈𝐈 (𝐇𝐢𝐬𝐭𝐨𝐥𝐨𝐠𝐲) to join our expert team. If you are passionate about advancing preclinical histology, driving innovation in digital pathology and contributing to impactful scientific programmes, this could be the perfect next step in your career.   At Axis Bioservices, you will have the opportunity to: • Lead complex histology projects across multiple therapeutic areas • Shape and optimise workflows in a fast‑advancing scientific environment • Collaborate with multidisciplinary teams dedicated to delivering high‑quality, actionable insights • Grow within an organisation that values expertise, curiosity, and continuous learning If you, or someone in your network would be a great fit, then we would love to hear from you!   Apply today and help us push the boundaries of preclinical science: https://lnkd.in/eNRniDqS   #Hiring #Histology #SeniorScientist #LifeSciences #DigitalPathology #AxisBioservices #JoinOurTeam #QIMALifeSciences

𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻‑𝗠𝗮𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝘂𝗺𝗼𝘂𝗿‑𝗠𝗼𝗱𝗲𝗹𝘀! Axis Bioservices Limited is proud to support QIMA Life Sciences in providing next‑generation preclinical oncology tools. This new prostate cancer flyer gives a clear view of how our tumour‑model platforms generate fast, clinic‑focused insights; helping sponsors refine strategy with confidence. #AxisBioservices #QIMALifeSciences #TumourModels #CancerResearch #PreclinicalOncology #NextGenModels #DrugDiscovery #TranslationalScience

𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐇𝐢𝐬𝐭𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 - 𝗝𝗼𝗶𝗻 𝗔𝘅𝗶𝘀 𝗕𝗶𝗼𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 🔬!   Axis Bioservices is rapidly expanding and we’re looking for a Senior Scientist I/II (Histology) to take the lead on delivering high‑impact histology and digital pathology projects. This role will be responsible for driving scientific excellence whilst ensuring that premium data is provided to our global clients.   📍 Limavady, Northern Ireland 💰 £35k – £45k (DOE)  📅 Permanent, full‑time    This is a fantastic opportunity to apply your expertise across tissue processing, staining, microscopy and quantitative digital pathology - mentoring others and shaping the evolution of our preclinical imaging capabilities. 𝐘𝐨𝐮𝐫 𝐌𝐢𝐬𝐬𝐢𝐨𝐧: ✔️ Lead and deliver high‑quality histology and digital pathology projects; managing all stages from tissue prep to microscopy  ✔️ Develop, optimise and validate H&E, special stains, IHC and IF protocols to ensure consistent technical excellence  ✔️ Acquire high‑resolution microscopy images and perform robust quantitative analysis using QuPath or equivalent software  ✔️ Integrate morphological and biomarker data into clear, scientifically rigorous project outputs  ✔️ Mentor junior scientists and contribute to a collaborative, innovation‑driven laboratory culture  ✔️ Prepare technical updates, reports and client communications to support study outcomes and scientific excellence 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲? Apply now: https://lnkd.in/ebBXKPGg   𝐖𝐚𝐧𝐭 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐀𝐱𝐢𝐬 𝐁𝐢𝐨𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬? Visit: https://www.axisbio.co.uk #AxisBioservices #QIMALifeScience #Histology #DigitalPathology #NorthernIreland #ScienceJobs #ResearchCareers #CareerGrowth

𝗪𝗼𝗿𝗹𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆 𝟮𝟬𝟮𝟲 - 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝘀 𝗣𝗼𝘀𝘀𝗶𝗯𝗹𝗲 💜!   Today on World Cancer Day, we stand alongside the global community to honour the millions of patients and families affected by cancer and to recognise the extraordinary dedication of the researchers, clinicians and innovators working tirelessly to advance prevention, diagnosis and treatment.    At Axis Bioservices Limited, our mission is driven by the belief that every data point, every discovery and every breakthrough contributes to a future where cancer is detected earlier, treated more effectively and understood more deeply. We are proud to support the scientific community by providing high‑quality preclinical research services that empower researchers to accelerate the development of life‑changing therapies. Everyday we remain inspired by the strength of patients whose experiences motivate progress across the field, the researchers who fuel innovation and the global community committed to beating cancer. We stand with you as we continue working together to close the care gap, drive scientific excellence and shape a healthier future. #WorldCancerDay #AxisBioservices #CancerResearch #LifeSciences #PreclinicalResearch #InnovateForImpact

𝗡𝗲𝘅𝘁‑𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗠𝗼𝗱𝗲𝗹𝘀: 𝗘𝘅𝗽𝗲𝗿𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀! As a key oncology provider within the QIMA Life Sciences group, Axis Bioservices Limited is committed to helping sponsors bridge the gap between preclinical insights and clinical success. To support this. we are proud to re-share a QIMA webinar where our very own Managing Director, Dr Jenny Worthington, joins Lara Bellini, PhD to unpack what truly makes a next‑generation preclinical model and why these innovations matter for today’s cancer drug pipelines. #AxisBioservices #CancerResearch #OncologyPreclinicalModels #DrugDevelopment #TranslationalScience #CancerTherapeutics #LifeSciences #QIMALifeSciences

𝐑𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐨𝐮𝐭𝐞 𝐭𝐨 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭: 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐀𝐜𝐭𝐢𝐨𝐧! Proud to see Axis Bioservices Limited represented at the heart of this QIMA Life Sciences discussion. In her latest interview, our Managing Director, Dr Jenny Worthington explains why translating cancer breakthroughs to the clinic is so challenging and how Axis can support smarter preclinical models for our clients. #AxisBioservices #Oncology #CancerResearch #TranslationalScience #PreclinicalModels #DrugDevelopment #ScientificLeadership #QIMALifeSciences

🚨 𝐍𝐞𝐰 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐑𝐞𝐥𝐞𝐚𝐬𝐞! Strong late-stage oncology outcomes start with well-designed discovery and preclinical studies. At Axis Bioservices Limited, we provide translational discovery and preclinical oncology services that help de-risk development from the very first screen. Proud to see our expertise featured alongside our partnered services within the QIMA Life Sciences group in this new brochure highlighting integrated 𝘪𝘯−𝘷𝘪𝘵𝘳𝘰 and preclinical strategies. #AxisBioservices #QIMALifeSciences #QIMAOncology #PreclinicalResearch #DrugDiscovery #TranslationalScience #CancerResearch #OncologyRD